Dupixent® (dupilumab) recommended for eu approval by the chmp for the treatment of eosinophilic esophagitis

If approved, dupixent would be the first and only targeted medicine specifically indicated for people aged 12 years and older with eosinophilic esophagitis in the european union in the u.s., dupixent is currently the only medicine indicated to treat eosinophilic esophagitis approval recommendation based on pivotal trial data demonstrating patients on dupixent 300 mg weekly experienced significantly improved ability to swallow and achieved histological disease remission compared to placebo in the european union, about 50,000 adults and adolescents live with severe uncontrolled eosinophilic esophagitis tarrytown, n.y. and paris , dec. 16, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today announced that the european medicines agency's committee for medicinal products for human use (chmp) has adopted a positive opinion, recommending the approval of dupixent® (dupilumab) in the european union (eu) to treat adults and adolescents with eosinophilic esophagitis (eoe).
REGN Ratings Summary
REGN Quant Ranking